Trial · NCT01282073

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

NCT01282073, Phase 3, Completed, Kyungpook National University Hospital; results first posted 2025-08-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy. Trials, record NCT01282073. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01282073

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
NCT number: NCT01282073
Status: Completed
Phases: Phase 3
Enrollment: 43 participants, actual
Lead sponsor: Kyungpook National University Hospital
Conditions: Glomerulonephritis, Membranous
Interventions: Mycophenolate mofetil, low dose steroid, Cyclosporin, low dose steroid
First posted: 2011-01-24
Last updated: 2025-08-27
Results first posted: 2025-08-27

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Complete Remission	at 48 week after treatment	Complete remission: Reduction in proteinuria to 200 mg per day with stable serum albumin with more than 3.5 g/dL
Primary	Percentage of Partial Remission	at 48 week after treatment	Partial remission: Reduction in proteinuria to greater than 50 percent of initial values or absolute values of proteinuria between 200 mg and 3.5 g per day
Secondary	Estimated Glomerular Filtration Rate (eGFR)	at 48 week after treatment	The change of eGFR mesured by Modification of Diet in Renal Disease (MDRD) study equation from baseline to 1 year after treatment
Secondary	Relapse	For 48 weeks after treatment	A relapse is return of proteinuria to approximately 3.5g/day in patients who had previously undergone a complete or partial remission
Secondary	Proteinuria	at 48 week after treatment	The change of proteinuria from baseline to 48 week after treatment
Secondary	Side Effects	For 48 weeks after treatment	Any undesired effects of interventional drugs

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percentage of Complete Remission	at 48 week after treatment	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Percentage of Partial Remission	at 48 week after treatment	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Estimated Glomerular Filtration Rate (eGFR)	at 48 week after treatment
SECONDARY	Relapse	For 48 weeks after treatment
SECONDARY	Proteinuria	at 48 week after treatment
SECONDARY	Side Effects	For 48 weeks after treatment

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Percentage of Complete Remission	Mycophenolate Mofetil, Low Dose Steroid	4	Participants
Percentage of Complete Remission	Cyclosporin, Low Dose Steroid	3	Participants
Percentage of Partial Remission	Mycophenolate Mofetil, Low Dose Steroid	12	Participants
Percentage of Partial Remission	Cyclosporin, Low Dose Steroid	9	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mycophenolate Mofetil, Low Dose Steroid	21
Overall Study	STARTED	Cyclosporin, Low Dose Steroid	18
Overall Study	COMPLETED	Mycophenolate Mofetil, Low Dose Steroid	21
Overall Study	COMPLETED	Cyclosporin, Low Dose Steroid	18
Overall Study	NOT COMPLETED	Mycophenolate Mofetil, Low Dose Steroid	0
Overall Study	NOT COMPLETED	Cyclosporin, Low Dose Steroid	0

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhea	Gastrointestinal disorders	Mycophenolate Mofetil, Low Dose Steroid	2	21
other	Diarrhea	Gastrointestinal disorders	Cyclosporin, Low Dose Steroid	2	18
other	Epigastric discomfort	Gastrointestinal disorders	Mycophenolate Mofetil, Low Dose Steroid	3	21
other	Epigastric discomfort	Gastrointestinal disorders	Cyclosporin, Low Dose Steroid	4	18
other	Anaemia	Blood and lymphatic system disorders	Mycophenolate Mofetil, Low Dose Steroid	1	21
other	Anaemia	Blood and lymphatic system disorders	Cyclosporin, Low Dose Steroid	1	18
other	Upper respiratory infection	Infections and infestations	Mycophenolate Mofetil, Low Dose Steroid	6	21
other	Upper respiratory infection	Infections and infestations	Cyclosporin, Low Dose Steroid	3	18
other	Urinary tract infection	Infections and infestations	Mycophenolate Mofetil, Low Dose Steroid	1	21
other	Urinary tract infection	Infections and infestations	Cyclosporin, Low Dose Steroid	0	18

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Mycophenolate Mofetil, Low Dose Steroid	0	21
Total, all-cause mortality	Cyclosporin, Low Dose Steroid	0	18
Total, other adverse events	Mycophenolate Mofetil, Low Dose Steroid	12	21
Total, other adverse events	Cyclosporin, Low Dose Steroid	9	18
Total, serious adverse events	Mycophenolate Mofetil, Low Dose Steroid	0	21
Total, serious adverse events	Cyclosporin, Low Dose Steroid	0	18

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29441742	DERIVED	PubMed
34778952	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: Percentage of Complete Remission	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: deaths from any cause	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: Percentage of Partial Remission	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01282073

GET https://conductscience.org/api/trials/v1/NCT01282073/registered

API reference For AI assistants